Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jun 20;39(18):2025-2036.
doi: 10.1200/JCO.20.03637. Epub 2021 Apr 20.

Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial

Affiliations
Clinical Trial

Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial

Yasuhisa Hasegawa et al. J Clin Oncol. .

Abstract

Purpose: This study aimed to compare patients with early oral cavity squamous cell carcinoma (OCSCC) (tumor category [T] 1-2, node-negative, and no distant metastasis) treated with traditional elective neck dissection (ND) with those managed by sentinel lymph node biopsy (SLNB) using survival and neck function and complications as end points.

Methods: Sixteen institutions in Japan participated in the study (trial registration number: UMIN000006510). Patients of age ≥ 18 years with histologically confirmed, previously untreated OCSCC (Union for International Cancer Control TNM Classification of Malignant Tumors 7th edition T1-2, node-negative no distant metastasis), with ≥ 4 mm (T1) depth of invasion, were randomly assigned to undergo standard selective ND (ND group; n = 137) or SLNB-navigated ND (SLNB group; n = 134). The primary end point was the 3-year overall survival rate, with a 12% noninferiority margin; secondary end points included postoperative neck functionality and complications and 3-year disease-free survival. Sentinel lymph nodes underwent intraoperative multislice frozen section analyses for the diagnosis. Patients with positive sentinel lymph nodes underwent either one-stage or second-look ND.

Results: Pathologic metastasis-positive nodes were observed in 24.8% (34 of 137) and 33.6% (46 of 134) of patients in the ND and SLNB groups, respectively (P = .190). The 3-year overall survival in the SLNB group (87.9%; lower limit of one-sided 95% CI, 82.4) was noninferior to that in the ND group (86.6%; lower limit 95% CI, 80.9; P for noninferiority < .001). The 3-year disease-free survival rate was 78.7% (lower limit 95% CI, 72.1) and 81.3% (75.0) in the SLNB and ND groups, respectively (P for noninferiority < .001). The scores of neck functionality in the SLNB group were significantly better than those in the ND group.

Conclusion: SLNB-navigated ND may replace elective ND without a survival disadvantage and reduce postoperative neck disability in patients with early-stage OCSCC.

PubMed Disclaimer

Conflict of interest statement

Akihiro HommaResearch Funding: Taiho Pharmaceutical, Ono Pharmaceutical, Eisai Co, Ltd, Eisai Co, Ltd Akihiro ShiotaniHonoraria: Kyorin, Mitsubishi Tanabe PharmaResearch Funding: Taiho Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Daiichi Sankyo/UCB Japan, Teijin Pharma, Takeda Yasushi YatabeConsulting or Advisory Role: MSD K.K, Chugai Pharma, AstraZeneca, Novartis, Amgen, Archer, Takeda, Daiichi Sankyo/UCB JapanSpeakers' Bureau: MSD K.K, Chugai Pharma, AstraZeneca, Novartis, Amgen, Archer, Pfizer, Ventana Medical Systems, Agilent, Thermo Fisher ScientificNo other potential conflicts of interest were reported.

Comment in

Publication types

MeSH terms

Associated data